Stockscreener 앱 받기
5.32
1.12%
-0.06
시간 외 거래:
5.27
-0.05
-0.94%
Alvotech 주식(ALVO)의 최신 뉴스
Alvotech (ALVO) Is Up 7.5% After FDA Accepts Review Of Key Entyvio Biosimilar AVT80 - simplywall.st
Alvotech and Lotus Enter Agreement for Durvalumab and Emicizumab Biosimilars - marketscreener.com
Alvotech (NASDAQ:ALVO) Shares Up 5.4%Here's What Happened - MarketBeat
FDA to review Alvotech (Nasdaq: ALVO) subcutaneous Entyvio biosimilar - Stock Titan
Alvotech Says FDA Accepted Biologics License Application for AVT80 - marketscreener.com
Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations - Yahoo Finance
Alvotech (ALVO) Is Up 11.7% After Lotus Biosimilar Licensing Deal and 2026 Guidance Update – Has The Bull Case Changed? - simplywall.st
Why Alvotech (ALVO) Is Up 11.7% After Expanding Biosimilar Deal With Lotus Pharmaceutical - Yahoo Finance
Alvotech (ALVO) Stock Still Trades At A Discount After A 57% Rally - simplywall.st
Alvotech to present at upcoming investor conferences in September - Yahoo Finance
Alvotech (ALVO) On FDA Clearance And Lotus Deal As Undervalued Narrative Gains Ground - simplywall.st
Taiwan's Lotus Pharma inks biosimilars agreement with Alvotech for US and selected Asian markets - BioSpectrum Asia
BofA starts bullish Alvotech coverage on biosimilar launch cycle - Investing.com
Why Alvotech (ALVO) Is Up 9.2% After $150 Million Lotus Biosimilar Deal And 2026 Update - Sahm
ALVOTECH ($ALVO) Releases Q2 2026 Earnings - Moomoo
Alvotech licenses durvalumab and emicizumab biosimilar candidates to Lotus in ~$150M deal - Dealroom
Alvotech Targets Three U.S. Biosimilar Decisions In Q4 After FDA Manufacturing Inspection Closes - pulse2.com
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Alvotech (ALVO) and Abbott Laboratories (ABT) - The Globe and Mail
Teleconferência de Resultados do 2T26 da Alvotech (ALVO): Guidance Reafirmado - TradingKey
Alvotech (NASDAQ:ALVO) Builds Momentum Around Biosimilar Expansion - Kalkine Media
Alvotech 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ALVO) 2026-08-21 - Seeking Alpha
Alvotech, Lotus Ink Biosimilar Licensing and Commercialization Pact in US, Asia - Contract Pharma
Alvotech (NASDAQ:ALVO) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Alvotech licenses two early-stage biosimilar candidates to Lotus for USD 150m - AllSci
Alvotech (NASDAQ: ALVO) bets on U.S. biosimilars with Lotus - Stock Titan
Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets - marketscreener.com
Alvotech Enters Strategic Licensing and Commercialization Agreement with Lotus Pharmaceutical for AVT34 and AVT87 - Quiver Quantitative
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for ... - Enidnews.com
Alvotech and Lotus sign deal for proposed versions of $6.1B and $5.8B medicines - Stock Titan
Alvotech Q2 2026 Earnings Call Transcript - Sahm
Alvotech (ALVO) Stock Rises On Guidance Resolve Despite Lingering Loss Risk - simplywall.st
Alvotech Files H1 2026 Results and Schedules Business Update Call - The Globe and Mail
Alvotech holds rating despite H1 2026 earnings miss and FDA delays, eyes multiple biosimilar approvals by Q4 2026. - Pluang
Alvotech earnings missed by $0.02, revenue fell short of estimates - Investing.com India
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts (ALVO) - Seeking Alpha
Alvotech (NASDAQ:ALVO) Trading 6.8% HigherHere's What Happened - MarketBeat
Alvotech Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Alvotech misses Q2 2026 estimates as revenue stalls - Investing.com
ALVO: Revenue and margins set to rebound in H2 as supply normalizes and portfolio expands - TradingView
Alvotech Q2 2026 Earnings Call Summary - Yahoo Finance
Alvotech Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Alvotech 1H Adjusted EBITDA $46.9 M >ALVO - Moomoo
Alvotech (ALVO) reports Q2 loss, beats revenue estimates - FXStreet
Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Iceland's Alvotech H1 revenue falls 31% on manufacturing program - TradingView
Alvotech (NASDAQ:ALVO) Releases Earnings Results, Misses Estimates By $0.17 EPS - MarketBeat
Alvotech Q2 Results: EPS Misses Estimate, Sales Fall 39% YoY - scanx.trade
Alvotech H1 Results: Revenue falls 31%, EBITDA down 13% - scanx.trade
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update - The Manila Times
Alvotech affirms FY26 sales guidance of $650M-$700M - scanx.trade
ALVO: Revenue and EBITDA fell in H1 2026, but outlook is strong as manufacturing recovers - TradingView
Alvotech H1 Reports Product Revenue USD 211.9 Million - TradingView
Alvotech (ALVO) raises $165M amid revenue drop and $72M interest hit - Stock Titan
Alvotech Announces Financial Results for the - Moomoo
Alvotech earnings on deck as FDA biosimilar decisions loom By Investing.com - Investing.com India
Alvotech earnings on deck as FDA biosimilar decisions loom - Investing.com
Earnings To Watch: Alvotech (ALVO) Q2 2026 -- GF Value Sees 461% Upside - Yahoo Finance
Alvotech Hires CGCN Group on Pharma Tariffs - Legis1
1.66%
0.33%
자본화:
|
볼륨(24시간):